Administration of avermectin/milbemycin compounds for the treatment of ophthalmic pathologies

Abstract

Administration of at least one compound of the family of the avermectins or of the family of the milbemycins, notably ivermectin, is useful for the treatment of ophthalmic pathologies, including ocular rosacea.

Description

CROSS-REFERENCE TO PRIORITY / PCT / PROVISIONAL APPLICATIONS[0001]This application claims priority under 35 U.S.C. § 119 of FR 0510025, filed Sep. 30, 2005, and of Provisional Application No. 60 / 725,320, filed Oct. 12, 2005, Provisional Application No. 60 / 818,316, filed Jul. 5, 2006, and is a continuation of PCT / IB 2006 / 003864 filed Sep. 29, 2006 and designating the United States, published in the English language as WO 2007 / 054822 A2 on May 18, 2007, each hereby expressly incorporated by reference in its entirety and each assigned to the assignee hereof.BACKGROUND OF THE INVENTION[0002]1. Technical Field of the Invention[0003]The present invention relates to the formulation of at least one compound of the family of the avermectins or of the family of the milbemycins into pharmaceutical compositions useful for the treatment of ophthalmic pathologies, including ocular rosacea.[0004]2. Description of Background and / or Related and / or Prior Art[0005]Ocular rosacea is frequently diagnosed wh...

AI Technical Summary

Benefits of technology

[0023]The term “pharmaceutical composition” means, according to the invention, a stable composition comprising a therapeutically active agent which has a good cosmetic quality and a satisfactory time limit (18 months minimum).

Problems solved by technology

However, not all ocular pathologies are related to the presence of this ectoparasite.

If ocular rosacea, which is included among ophthalmic pathologies, is not treated, serious complications may occur in the cornea and this can detrimentally affect the vision.

This treatment is used in first application, during severe attacks on the eyes, due to the risk of after-effects on the eyes.

An antibiotic of the class of the macrolides (erythromycin) can also be administered but the response to the treatment is not systematic.

None of these treatments makes possible complete and lasting remission of ocular rosacea.

Its attachment to these channels promotes an increase in the membrane permeability to chloride ions, resulting in hyperpolarization of the nerve or muscle cell.

This results in neuromuscular paralysis, which can bring about the death of certain parasites.

Specifically, the facts indicated in this patent do not suggest to one skilled in this art anything regarding the feasibility and the effectiveness of pharmaceutical compositions acceptable industrially for the treatment of ocular rosacea.